Darzalex
Daratumumab Delays Transition From Smoldering to Active Multiple Myeloma
In a phase 3 trial, the anti-38 monoclonal antibody daratumumab (Darzalex, Johnson & Johnson) substantially ...
FEBRUARY 19, 2025
New Standard of Care Declared for First-Line Regimen in Multiple Myeloma
By adding daratumumab (Darzalex, Janssen Oncology), a CD38-specific IgG1 antibody, to conventional immunomodulatory ...
DECEMBER 18, 2023
FDA Approves Darzalex + Kyprolis for Relapsed or Refractory MM
The FDA granted approval to daratumumab (Darzalex, Janssen) in combination with carfilzomib (Kyprolis, Amgen) and ...
AUGUST 24, 2020
Darzalex Plus VTd Approved for Newly Diagnosed HCT-Eligible Multiple Myeloma
The FDA approved daratumumab (Darzalex, Janssen) in combination with VTd (bortezomib, thalidomide, dexamethasone) ...
SEPTEMBER 30, 2019
FDA Approves Darzalex for Newly Diagnosed MM
The FDA granted a new indication for daratumumab in combination with lenalidomide and dexamethasone for the ...
JUNE 28, 2019
FDA Approves Split-Dose Regimen for Darzalex
Splitting the first dose of daratumumab over two consecutive days reduced the duration of the first infusion, and ...
FEBRUARY 13, 2019
Adding Daratumumab Extends PFS in Transplant-Ineligible MM
San Diego—When added to the standard combination of lenalidomide and dexamethasone in previously untreated ...
FEBRUARY 8, 2019
Darzalex Approved to Treat Newly Diagnosed MM Patients
The FDA approved daratumumab (Darzalex, Janssen) in combination with VMP (bortezomib [Velcade, Millennium], ...
MAY 9, 2018
Darzalex Approved With Pomalyst and Dex for Third-Line MM Rx
Approved in combination with pomalidomide (Pomalyst, Celgene) and dexamethasone for patients with multiple myeloma ...
JUNE 19, 2017
